Cathy Smith - Baxter International Independent Director
| BAX Stock | USD 33.44 0.65 1.91% |
Director
Ms. Cathy R. Smith serves as Independent Director of the Company Ms. Smith is Executive Vice President and Chief Financial Officer at Target Corporation, a retailer. As previously disclosed by Target, Ms. Smith has announced her intention to retire from Target effective May 1, 2020. She will continue serving as Targets Chief Financial Officer until her successor was appointed, after which time she has agreed to provide strategic advisory services through her retirement date. Prior to joining Target in 2015, Ms. Smith served as Executive Vice President and Chief Financial Officer at Express Scripts Holding Company,, an independent pharmacy benefits management company, from 2014 to 2015 and as Executive Vice President, Strategy and Chief Financial Officer at Walmart International, a division of Walmart Stores Inc., a discount retailer, from 2010 to 2014. Significant financial expertise and corporate leadership experience as a result of her senior positions held at Target, Express Scripts and Walmart. This experience includes work helping to oversee cybersecurity incident response. since 2017.
| Age | 57 |
| Tenure | 8 years |
| Address | One Baxter Parkway, Deerfield, IL, United States, 60015 |
| Phone | 224 948 2000 |
| Web | https://www.baxter.com |
Baxter International Management Efficiency
The company has Return on Asset of 0.0205 % which means that on every $100 spent on assets, it made $0.0205 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.0421) %, meaning that it generated no profit with money invested by stockholders. Baxter International's management efficiency ratios could be used to measure how well Baxter International manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -0.02 in 2025. Return On Capital Employed is likely to rise to -0.0055 in 2025. At this time, Baxter International's Non Currrent Assets Other are fairly stable compared to the past year. Other Current Assets is likely to rise to about 3.5 B in 2025, whereas Total Assets are likely to drop slightly above 16.5 B in 2025.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Jan Witte | ResMed Inc | 56 | |
| Bertram Scott | Becton Dickinson and | 69 | |
| Candace Duncan | Teleflex Incorporated | 67 | |
| Richard Sulpizio | ResMed Inc | 70 | |
| Claire Fraser | Becton Dickinson and | 65 | |
| Arthur MD | Alcon AG | 63 | |
| Mark Buthman | West Pharmaceutical Services | 60 | |
| Harjit Gill | ResMed Inc | 55 | |
| George Babich | Teleflex Incorporated | 69 | |
| Robert Friel | West Pharmaceutical Services | 65 | |
| Richard Packer | Teleflex Incorporated | 62 | |
| William Feehery | West Pharmaceutical Services | 50 | |
| John Heinmiller | Teleflex Incorporated | 66 | |
| Catherine Burzik | Becton Dickinson and | 70 | |
| Gary Petersmeyer | The Cooper Companies, | 73 | |
| Myla LaiGoldman | West Pharmaceutical Services | 62 | |
| Karen Drexler | ResMed Inc | 60 | |
| Carol Burt | ResMed Inc | 62 | |
| Ronald Taylor | ResMed Inc | 72 | |
| Maria Rivas | The Cooper Companies, | 57 | |
| Andrew Krakauer | Teleflex Incorporated | 66 | |
Management Performance
| Return On Equity | -0.0421 | ||||
| Return On Asset | 0.0205 |
Baxter International Leadership Team
Elected by the shareholders, the Baxter International's board of directors comprises two types of representatives: Baxter International inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Baxter. The board's role is to monitor Baxter International's management team and ensure that shareholders' interests are well served. Baxter International's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Baxter International's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Andrew Frye, Senior Vice President and President APAC | ||
| David Rosenbloom, Executive Counsel | ||
| Jacqueline Kunzler, Senior Vice President and Chief Quality Officer | ||
| Anita Zielinski, Chief VP | ||
| Nancy Schlichting, Independent Director | ||
| Brik Eyre, Senior Vice President, President - Americas | ||
| Michael Mahoney, Independent Director | ||
| Heather Knight, Executive Therapies | ||
| Stacey Eisen, Senior Communications | ||
| Charles Patel, Senior Officer | ||
| Talvis Love, Senior Officer | ||
| Amy McbrideWendell, Independent Director | ||
| John Forsyth, Independent Director | ||
| Jeanne Mason, Senior Vice President - Human Resources | ||
| Brian Stevens, Senior Vice President Chief Accounting Officer, Controller | ||
| Scott Pleau, Corporate Vice President - Operations | ||
| Cathy Smith, Independent Director | ||
| David Shafer, Chair CEO | ||
| David Wilkes, Independent Director | ||
| Albert Stroucken, Lead Independent Director | ||
| James Borzi, Senior Vice President Chief Supply Chain Officer | ||
| Mba BE, Executive Pharmaceuticals | ||
| James Gavin, Independent Director | ||
| Ellen Bradford, Senior Secretary | ||
| Thomas Chen, Independent Director | ||
| Piero Novello, Senior Markets | ||
| Clare Trachtman, Vice President Investor Relations | ||
| Amy Wendell, Independent Director | ||
| Peter Hellman, Lead Independent Director | ||
| Reazur Rasul, Executive Technologies | ||
| Gerard Greco, Senior Officer | ||
| Jose Almeida, Chairman of the Board, President, Chief Executive Officer | ||
| James Saccaro, Chief Financial Officer, Executive Vice President | ||
| Thomas Stallkamp, Lead Independent Director | ||
| Patricia Morrison, Independent Director | ||
| MS MD, Senior Officer | ||
| Christopher Toth, Executive Care | ||
| Joel Grade, Executive CFO | ||
| Giuseppe Accogli, Senior Vice President and Presidentident - Global Businesses | ||
| Stephen Oesterle, Independent Director | ||
| Sean Martin, Corporate Vice President General Counsel | ||
| Cristiano Franzi, Senior Vice President and President EMEA |
Baxter Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Baxter International a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0421 | ||||
| Return On Asset | 0.0205 | ||||
| Profit Margin | (0.06) % | ||||
| Operating Margin | 0.10 % | ||||
| Current Valuation | 29.13 B | ||||
| Shares Outstanding | 511.62 M | ||||
| Shares Owned By Insiders | 0.38 % | ||||
| Shares Owned By Institutions | 97.74 % | ||||
| Number Of Shares Shorted | 20.99 M | ||||
| Price To Earning | 27.05 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Baxter Stock Analysis
When running Baxter International's price analysis, check to measure Baxter International's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Baxter International is operating at the current time. Most of Baxter International's value examination focuses on studying past and present price action to predict the probability of Baxter International's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Baxter International's price. Additionally, you may evaluate how the addition of Baxter International to your portfolios can decrease your overall portfolio volatility.